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The use of cannabis as a therapeutic and recreational sub-
stance goes back to thousands of years throughout Asia, Mid-
dle East, Southern Africa, and South America. The discovery
of Δ-9-tetrahydrocannabinol (Δ9-THC) by Mechoulam and
Gaoni in themidsixties as themajor psychoactive constituent
of cannabis sativa [1, 2] led to another important discovery,
namely, its specific binding site that was isolated and cloned
in 1990 [3]. This first cannabinoid receptor was coined CB1R
and triggered a number of investigations on its expression,
localization, and function within the body tissue including
the brain, in various species.This was followed by the discov-
ery in 1992 of the first endocannabinoid (eCB), anandamide
[4], followed by another cannabinoid receptor CB2R and a
second endocannabinoid called 2-arachidonoylglycerol (2-
AG) [5, 6]. Later on, some of the enzymes responsible for their
synthesis (N-acyl phosphatidylethanolamine phospholipase
D (NAPE-PLD); diacylglycerol lipase (DAGL)) and degrada-
tion (fatty acid amide hydrolase (FAAH); monoacylglycerol
lipase (MAGL)) were identified.
The recreational use and side effects of cannabinoids
have been subjected to numerous studies throughout history
and the list of neurobehavioral effects of chronic use of
marijuana is long and well known. For example, significant
impairments have been reported on the visual system (e.g.,
photosensitivity, depth perception, color, motion, scotopic,
and photopic functions) [7, 8], the motor system (movement
control and coordination in driving) [9, 10], motivations
(e.g., increased hunger known as “munchies”) [11], higher
cognitive functions (reward, cognition, learning, and mem-
ory) [12], and emotions (e.g., fear, depression, anxiety, and
paranoia) [13] have been reported. However, the investigation
of the endocannabinoid (eCB) system and its potential
therapeutic use is rather new, and a lot of attention has been
devoted not only to its specific expression in the brain but also
to its functions. Studies on the expression and localization
of the cannabinoid receptors in the brain have burgeoned
in the last decade and have furnished valuable data on their
putative involvement in various sensory-motor and cognitive
functions in diverse animal species, including Man. These
studies have recently received substantial attention from
pharmaceutical companies as a potential source for novel
treatments. Additionally, the dilemma of legalizing the use
of cannabis in some countries makes the investigation on
cannabinoid systems more momentous. This special issue is
therefore timely and brings historical and groundbreaking
novel research on the role of these cannabinoid receptors in
the mammalian central nervous system (CNS).
In this issue, we present a number of review papers and
original articles on the eCB system ranging from vision to
cognition in mice, rats, tree shrews, monkeys, and humans.
Cannabinoid exposure during adolescence increases the
effects of certain drugs [14]. In their original article, M.
Rodr´ıguez-Arias et al. demonstrate that exposure of ado-
lescent male mice to WIN 55212-2 (a cannabinoid agonist)
increases the cocaine rewarding effects. They also conclude
that the development of drug addiction is dependent on
the propensity for sensation-seeking. Heavy and prolonged
cannabis consumption by teenagers could as well produce
a wide range of structural and functional modifications in
the brain [15, 16]. In their research paper, S. J. Broyd and
colleagues evaluate the recovery of mismatch negativity and
the P50 sensory gating in cannabis ex-users. They conclude
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that the modifications induced by cannabis usage during
adolescence are persistent even after a prolonged period of
abstinence.
Until recently, the vast majority of the cannabinoid effects
in the CNS were attributed exclusively to the CB1R. However,
recent evidence also demonstrates the presence of the CB2R
in the nervous system (for review, see [17]). Using CB2R
knockout (KO) mice, Y. Li and J. Kim assess the role played
by the CB2R in memory. They demonstrate that, depending
on the memory type, CB2R plays different roles. For exam-
ple, CB2R affects preferentially the hippocampus-dependent
memory such as long-termcontextual fearmemory.They also
show that the CB2R KO mice have an enhanced working
memory.
Two original research articles on the retina are proposed
by the Montreal group. In the first one, the authors provide
interesting data on interspecies comparisons of the distribu-
tion and localization of cannabinoid receptors. Since most
of the data, to this day, has been collected on rodents, J.
Bouskila and collaborators provide results on four species
along the phylogenetic scale and show major differences
between them. The expression of CB1R, FAAH, MAGL, and
DAGL is similar for all species whereas CB2R and NAPE-
PLD are differently expressed. In monkeys, NAPE-PLD is
restricted to the photoreceptor layer and CB2R is found in
Mu¨ller cells only. In the second paper, J. Bouskila et al.
propose a functional role of CB1R andCB2R in primate vision
using electroretinographic recordings (ERG).They show that
blockade of either CB1R or CB2R by the intravitreal injection
of specific antagonists has differential effects. In photopic
conditions, blocking CB1R increases the amplitude of the a-
wave of the ERG whereas blocking CB2R increases both a-
and b-waves.
The papers by J.-F. Bouchard et al. and T. Schwitzer et
al. provide extensive and up-to-date reviews on cannabinoid
research. In their review, J.-F. Bouchard et al. characterize
the expression and physiological functions of the eCB system
in the visual system, from the retina to the primary visual
cortex. They report that eCB system is widely present in
the retina, where it acts as a modulator of neurotransmitter
release and ion channel activity. T. Schwitzer et al., besides
reviewing the distribution of the eCB system throughout the
retina, describe the crucial role of the cannabinoid system
in neurotransmission, neural plasticity, and neuroprotection.
Both reviews highlight the potential use of cannabinoids as
therapeutic pharmacological agents for the protection and
treatment of retinal diseases.
Retinal diseases as glaucoma receive a particular attention
in the next two reviews. E. A. Cairns et al. review the evidence
of eCB as a potential target for the treatment of glaucoma and
propose that this system has also a neuroprotective function.
D. Kokona et al. present, besides glaucoma, research on other
retinal pathologies such as diabetic retinopathy.These retinal
neurodegenerative diseases lead to massive retinal neuron
loss and lead to blindness. The neuroprotective putative role
of eCB is also highlighted here.
In order to study the physiological and the pathophys-
iological effects of eCBs (anandamide, 2-AG, PEA, etc.) in
the CNS, we need to quantify their levels. In their article, J.
Keereetaweep and K. D. Chapman review the recent and sen-
sitive mass spectrometry methods allowing the development
of lipidomic approaches andmethodologies to quantify these
lipid mediators in the CNS.
We hope that the collected papers in this special issue will
contribute to the understanding of the various mechanisms
involved in the functions of the endocannabinoid system and
the development of new pharmaceutical tools to treat visual
disorders.
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